Company intelligence / Profile preview

Advanced BioDesign

Lyon/Saint-Priest, Auvergne-Rhône-Alpes, Francepmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Employees: ~49
Development stage: Other

Overview

Preliminary results from the ODYSSEY first-in-human study with lead candidate ABD‑3001 in relapsed AML patients show good safety and biological activity at all doses tested. Over 65% of patients showed preliminary signs of efficacy, with some experiencing long-term benefit. The next phase will further assess efficacy over full treatment cycles.

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

4 assets

dimethyl ampal thiolester

3 more assets in the full pipeline.

Request access →

Partnerships

No major pharma partnerships disclosed as of May 2025; seeking partners for pivotal trials and commercialization.

Beyond the preview

Go deeper on Advanced BioDesign.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Advanced BioDesign.

Explore the full profile